12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Company News  |  Deals

Kite Pharma, National Institutes of Health deal

NIH's National Cancer Institute granted Kite exclusive access to current and future engineered peripheral blood autologous T cell therapeutics to treat hematological and solid cancers. Kite will also have an exclusive option to license...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >